Isatuximab
- Generic Name
- Isatuximab
- Brand Names
- Sarclisa
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1461640-62-9
- Unique Ingredient Identifier
- R30772KCU0
- Background
Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line. Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic antibody targeted against CD38, a glycoprotein found on th...
- Indication
Isatuximab is indicated in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma in adults who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. It is also indicated in combination carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple ...
- Associated Conditions
- Multiple Myeloma (MM), Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 177
- Registration Number
- NCT03530683
- Locations
- 🇺🇸
LAC+USC Medical Center, Los Angeles, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Northside Hospital, Atlanta, Georgia, United States
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
- Conditions
- Interventions
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 246
- Registration Number
- NCT03104842
- Locations
- 🇩🇪
Vivantes Am Urban, Berlin, Germany
🇩🇪Städt. Kliniken Bielefeld Klinikum Mitte, Bielefeld, Germany
🇩🇪Campus Benjamin Franklin Charite Berlin, Berlin, Germany
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 307
- Registration Number
- NCT02990338
- Locations
- 🇨🇿
Investigational Site Number : 2030001, Olomouc, Czechia
🇨🇿Investigational Site Number : 2030004, Hradec Kralove, Czechia
🇵🇱Investigational Site Number : 6160005, Krakow, Malopolskie, Poland
Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
- Conditions
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT02960555
- Locations
- 🇺🇸
Mount Sinai Hospital, New York, New York, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma
- First Posted Date
- 2015-08-04
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 55
- Registration Number
- NCT02514668
- Locations
- 🇺🇸
Investigational Site Number 840013, Canton, Ohio, United States
🇺🇸Investigational Site Number 840003, Scottsdale, Arizona, United States
🇫🇷Investigational Site Number 250008, Creteil Cedex, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.